SemBioSys’ Plant-Made Biosimilar Insulin Featured on CTV News, Canada AM
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
SemBioSys Genetics Inc. has announced that its Biosimilar Insulin program was featured last night on CTV National News and this morning on Canada AM.
The news story and interview highlighted the Company’s plant-based production technology for the highly scalable manufacture of Biosimilar Insulin (SBS-1000).
In March 2009, SemBioSys announced that in a phase I/II trial SBS-1000 was deemed bioequivalent to Eli Lilly’s Humulin® R, a commercially available human insulin.
“Plants have been a source of medicine for thousands of years. The innovative nature of our plant-produced platform is drawing interest from pharmaceutical companies due to its ability to provide a low cost insulin alternative for patients that suffer from this chronic disease,” said James Szarko, President and CEO of SemBioSys Genetics Inc. “We have received new, and renewed, interest from counterparties that could potentially become international commercialization partners for our Biosimilar Insulin. We are particularly focused on developing world markets where cost-effective insulin enables access to this life-saving therapy.”
The news story and interview highlighted the Company’s plant-based production technology for the highly scalable manufacture of Biosimilar Insulin (SBS-1000).
In March 2009, SemBioSys announced that in a phase I/II trial SBS-1000 was deemed bioequivalent to Eli Lilly’s Humulin® R, a commercially available human insulin.
“Plants have been a source of medicine for thousands of years. The innovative nature of our plant-produced platform is drawing interest from pharmaceutical companies due to its ability to provide a low cost insulin alternative for patients that suffer from this chronic disease,” said James Szarko, President and CEO of SemBioSys Genetics Inc. “We have received new, and renewed, interest from counterparties that could potentially become international commercialization partners for our Biosimilar Insulin. We are particularly focused on developing world markets where cost-effective insulin enables access to this life-saving therapy.”
